Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- Conditions
- Recurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- Other: cytology specimen collection procedureOther: laboratory biomarker analysis
- Registration Number
- NCT02178163
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Brief Summary
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor treatment to target the specific mutations.
- Detailed Description
PRIMARY OBJECTIVES:
I. To assess the percentage of advanced non-small cell lung cancer patients in whom therapy can be initiated based on genomic analysis of tumor specimens.
SECONDARY OBJECTIVES:
I. To estimate the percentage of patients in whom genomic analysis can be performed.
II. To assess the progression free survival and response rate in patients who start therapy based on the genomic analyses results.
OUTLINE:
Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, polymerase chain reaction (PCR), and microarray. Based on the results of the genomic analysis, patients may begin therapy.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then every 12 months thereafter.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1020
- Stage IV or recurrent Non-Small Cell Lung Cancer patients who either have archival tissue for genomic analysis or are willing to undergo a new biopsy to obtain tumor tissue for genomic analysis. Patients whose tumor has already undergone genomic analysis will be eligible.
- Zubrod performance status 0-2
- Life expectancy >= 3 months
- Absolute neutrophil count of > 1.5 x 10^9/L
- Platelet count > 100,000 x 10^9/L
- Serum creatinine =< 1.5 times the institutional upper limit of normal (ULN) or calculated creatinine clearance (Cockcroft-Gault formula) of > 45 mL/min
- Serum bilirubin =< 1.5 X ULN
- Transaminases (serum glutamic oxaloacetic transaminase [SGOT] and/or serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times institutional ULN and alkaline phosphatase =< 2.5 times ULN, unless patient has liver metastases and the managing physician believes that the elevation in liver enzymes is only related to the liver metastases
- Laboratory tests should be done within 30 days of enrollment on the trial
- A biopsy of the patient's tumor for genomic profiling is required; this biopsy specimen can be an already obtained diagnostic specimen provided the patient has not received systemic therapy since the biopsy has been obtained and was obtained within 60 days of trial enrollment. The biopsy material cannot be from a tumor site that has been radiated.
- Signed informed consent that details the investigational nature of the study according to institutional and federal guidelines
- Patients with concurrent malignancy; patients with prior or concurrent malignancy will be allowed as long as the treating physician considers it unlikely to impact the clinical outcome of the patient
- Serious medical illness including but not limited to uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction or cerebrovascular event with 6 months of registration, history of chronic active hepatitis or history of human immunodeficiency virus (HIV) or an active bacterial infection will not be eligible
- Pregnant or lactating women; female patients of child bearing potential will be informed that if they do enroll on a therapeutic trial, based on the genomic analyses, that they may not be able to enroll on a clinical trial if they are pregnant; all sexually active patients will be informed that patients enrolling on a therapeutic trial have to use contraceptive methods to prevent pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ancillary-Correlative (comprehensive genomic analysis) cytology specimen collection procedure Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy. Ancillary-Correlative (comprehensive genomic analysis) laboratory biomarker analysis Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
- Primary Outcome Measures
Name Time Method Proportion of patients receiving therapy based on genomic analyses among all eligible patients Up to 21 days Will be estimated with 95% confidence interval (CI) using the Wilson's method.
- Secondary Outcome Measures
Name Time Method Overall response rate assessed according to Response Evaluation Criteria in Solid Tumors 1.1 Up to 2 years Response rate will be estimated with 95% Wilson's CI.
Progression free survival (PFS) Time from the date of start of therapy based on genomic analysis until the date that progressive disease or death whichever is first reported, assessed up to 2 years PFS will be estimated and may also be summarized within subgroups using descriptive statistics (Kaplan and Meier) if there are sufficient data.
Overall survival (OS) From date of registration to up to 2 years Not all patients enrolled on the study will receive therapy based on genomic analyses therefore survival will be analyzed for patients who receive therapy based on genomic analyses, for patients who don't receive therapy based on genomic analyses and for the entire patient population. OS will be estimated and may also be summarized within subgroups using descriptive statistics (Kaplan and Meier) if there are sufficient data.
Trial Locations
- Locations (11)
KCI at McLaren Central Michigan
🇺🇸Mount Pleasant, Michigan, United States
KCI at Northern Michigan
🇺🇸Petoskey, Michigan, United States
KCI at McLaren Flint
🇺🇸Flint, Michigan, United States
KCI at McLaren Macomb
🇺🇸Mount Clemens, Michigan, United States
KCI At McLaren Clarkston
🇺🇸Clarkston, Michigan, United States
KCI at McLaren Lapeer Region
🇺🇸Lapeer, Michigan, United States
KCI at McLaren Port Huron
🇺🇸Port Huron, Michigan, United States
KCI at McLaren Bay Region
🇺🇸Bay City, Michigan, United States
KCI at Mclaren Bloomfield Hills
🇺🇸Bloomfield Hills, Michigan, United States
KCI at McLaren Greater Lansing, Mid Michigan Physicians
🇺🇸Lansing, Michigan, United States
Barbara Ann Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States